Abstract
2,4,6-Trichlorophenyl hydrazones 1-35 were synthesized and their in vitro antiglycation potential was evaluated. Compounds 14 (IC50 = 27.2 ± 0.00 μM), and 18 (IC50 = 55.7 ± 0.00 μM) showed an excellent activity against glycation of protein, better than the standard (rutin, IC50 = 70 ± 0.50 μM). This study thus identified a novel series of antiglycation agents. A structure-activity relationship has been studied, and all the compounds were characterized by spectroscopic techniques.
Keywords: 2,4,6-trichlorophenyl hydrazones, Schiff bases, Antiglycation, AGEPs, Glycation of protein., vitro antiglycation, spectroscopic, techniques, chemotherapeutic Schiff, antibacterial, antiproliferative
Medicinal Chemistry
Title: Synthesis of 2,4,6-Trichlorophenyl Hydrazones and their Inhibitory Potential Against Glycation of Protein
Volume: 7 Issue: 6
Author(s): Khalid Mohammed Khan, Zarbad Shah, Viqar Uddin Ahmad, Momin Khan, Muhammad Taha, Fazal Rahim, Humera Jahan, Shahnaz Perveen and M. Iqbal Choudhary
Affiliation:
Keywords: 2,4,6-trichlorophenyl hydrazones, Schiff bases, Antiglycation, AGEPs, Glycation of protein., vitro antiglycation, spectroscopic, techniques, chemotherapeutic Schiff, antibacterial, antiproliferative
Abstract: 2,4,6-Trichlorophenyl hydrazones 1-35 were synthesized and their in vitro antiglycation potential was evaluated. Compounds 14 (IC50 = 27.2 ± 0.00 μM), and 18 (IC50 = 55.7 ± 0.00 μM) showed an excellent activity against glycation of protein, better than the standard (rutin, IC50 = 70 ± 0.50 μM). This study thus identified a novel series of antiglycation agents. A structure-activity relationship has been studied, and all the compounds were characterized by spectroscopic techniques.
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Shah Zarbad, Uddin Ahmad Viqar, Khan Momin, Taha Muhammad, Rahim Fazal, Jahan Humera, Perveen Shahnaz and Iqbal Choudhary M., Synthesis of 2,4,6-Trichlorophenyl Hydrazones and their Inhibitory Potential Against Glycation of Protein, Medicinal Chemistry 2011; 7 (6) . https://dx.doi.org/10.2174/157340611797928415
DOI https://dx.doi.org/10.2174/157340611797928415 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Solvent-Free Synthesis of 4,5-Dihydropyrano[c]chromene Derivatives Over TiO<sub>2</sub> Nanoparticles as an Economical and Efficient Catalyst
Current Catalysis The Glutamatergic Neurotransmission in the Central Nervous System
Current Medicinal Chemistry Advanced Glycation: A Novel Outlook on Atherosclerosis
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Role of Neurotrophins in Spinal Plasticity and Locomotion
Current Pharmaceutical Design Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets SS31, a Small Molecule Antioxidant Peptide, Attenuates β-Amyloid Elevation, Mitochondrial/Synaptic Deterioration and Cognitive Deficit in SAMP8 Mice
Current Alzheimer Research Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
Current Stem Cell Research & Therapy Lentiviral Transgenesis - A Versatile Tool for Basic Research and Gene Therapy
Current Gene Therapy The Effect of Modified-Release Ketoconazole on Insulin Resistance in Patients with Severe Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Prevalence and Prognostic Value of Depression and Anxiety in Patients with Diabetic Foot Ulcers and Possibilities of their Treatment
Current Diabetes Reviews Ryanodine Receptor Patents
Recent Patents on Biotechnology Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design